Clinical Trials Browser

Prostatic Neoplasms

NCT06568172 2026-04-20

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Phase 3 Recruiting

420 enrolled

DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

NCT05624996 2026-04-03

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

474 enrolled

Thoracic

Lung Neoplasms

NCT06532279 2026-04-03

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Phase 2 Recruiting

98 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT05328505 2026-03-24

MIDAS-Prostate

Phase NA Recruiting

80 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms, Recurrence

NCT03493425 2026-03-23

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

Phase 2 Recruiting

82 enrolled

Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7

NCT07348887 2026-03-04

RTL-DART

Phase NA Recruiting

50 enrolled

Head & Neck

Squamous Cell Cancer of Head and Neck (SCCHN)

NCT04983095 2026-02-17

METRO

Phase NA Recruiting

118 enrolled

Genitourinary

Prostate Cancer Metastatic

NCT06547398 2026-02-05

Prostate Adaptive Radiation Therapy

Phase NA Recruiting

130 enrolled

Genitourinary

Prostatic Neoplasms

NCT06650033 2026-02-05

Pelvis ART

Phase NA Recruiting

280 enrolled

Gynecologic

Pelvic Neoplasms

NCT06499870 2025-10-21

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Phase 2 Recruiting

50 enrolled

Genitourinary

Prostate Adenocarcinoma

NCT06549478 2025-09-17

Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases

Phase 1 Recruiting

24 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06546267 2025-06-11

PROST-ART

Recruiting

2,500 enrolled

Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

NCT06306170 2025-04-22

GYN-ART

Recruiting

1,000 enrolled

Radiation Injuries, Disease Progression

NCT06216171 2024-09-27

ProHEART

Phase NA Recruiting

30 enrolled

Head & Neck

Head and Neck Neoplasms

NCT06330909 2024-03-26

HypoF-SBRT

Phase NA Recruiting

374 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

DIVINE

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

MIDAS-Prostate

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

RTL-DART

METRO

Prostate Adaptive Radiation Therapy

Pelvis ART

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases

PROST-ART

GYN-ART

ProHEART

HypoF-SBRT